RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort
Leukemia · 2023
DOI: 10.1038/s41375-023-02027-3 ↗Kurz gefasst
Leserbrief in der Zeitschrift Leukemia, 2023. Verfasst von J M O'Sullivan und 10 weiteren Autor:innen. Beteiligte Einrichtung: NIHR Biomedical Research Centre and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. jen…. Hauptthemen laut MEDLINE: Primary Myelofibrosis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Cancer Research UK, RCUK | Medical Research Council.
Abstract (Originalsprache)
The treatment of myelofibrosis (MF), a myeloproliferative neoplasm (MPN) driven by JAK-STAT pathway activating mutations, evolved with the advent of JAK inhibitors. The first-in-class agent, ruxolitinib (RUX), a JAK1/2 inhibitor, is now standard for treatment of splenomegaly and MF-associated symptoms [ 1 ]. However, MF is a biologically and clinically heterogeneous disease with certain difficult to treat patient subgroups. In particular, disease- or treatment-associated thrombocytopenia is associated with adverse outcomes [ 2 , 3 ] and often requires RUX dose reductions or interruptions which may limit treatment efficacy. Thrombocytopenic patients who discontinue RUX have a median survival of less than 1 year [ 3 ]. Pacritinib (PAC), a JAK2/IRAK1/ACVR1 inhibitor that spares JAK1, has shown clinical benefit in thrombocytopenic MF in the PERSIST-1 and -2 trials [ 4 , 5 ]. PAC203 was a randomized dose finding study of PAC in primary or secondary MF patients who were refractory or intolerant to RUX (RUX-ref/int), including patients with moderate and severe thrombocytopenia. Patients were randomized 1:1:1 (PAC 100 mg once daily [QD], 100 mg twice daily [BID] or 200 mg BID) stratified by baseline platelet count. This study established PAC 200 mg BID as the optimal efficacious and safe dose [ 6 ] and PAC is now FDA approved for the treatment of patients with MF who have thrombocytopenia. Previous studies established the adverse prognostic implications of certain somatic gene mutations in MF; specifically mutations in epigenetic ( ASXL1 , EZH2 ) [ 7 ], splicing factor ( SRSF2 , U2AF1 ) [ 7 ] and IDH1 / IDH2 genes [ 7 ] are associated with disease progression and shortened survival. Reduced likelihood of RUX response has been associated with ≥3 mutations [ 8 ] but not with mutation type [ 9 , 10 ]. Shorter time to RUX failure has been reported in those with ASXL1 / EZH2 mutations [ 9 ] and reduced time to RUX discontinuation in patients with ≥3 mutations [ 8 ]. Specific cytokine signatures have been correlated with RUX resistance [ 11 ] suggesting possible biologically relevant pathways (e.g. NFκB) mediating resistance. The mutation profiles of RUX-ref/int thrombocytopenic MF patients have not been well delineated. This represents a group with a major unmet need for effective management strategies, and a better understanding of their mutation profiles will assist the application of precision medicine in this challenging group. We therefore performed mutational analysis on a subgroup the PAC203 cohort (110 patients at baseline and 42 patients at 24 weeks follow-up using a 32-gene TruSeq Custom Amplicon Panel (see Supplementary Methods ). Furthermore, we interrogated cytokine profiles to understand the relationship between inflammatory signatures and clinico-genomic profiles in this cohort. Characteristics of this group was representative of the overall PAC203 cohort [ 6 ]. Median follow-up time was 213 (95% confidence interval [CI]: 189–236) days. The median age was 68 (37–87) years, the median duration of prior exposure to RUX was 1.59 years (range 0–11 years) with 72.7% reporting prior exposure to non-RUX therapies (range 1–5 lines). Primary myelofibrosis (PMF) was the most prevalent disease category (56.4%, 62/110), followed by post-polycythemia vera MF (PPV-MF) in 29.1% (32/110) and post-essential thrombocythemia MF (PET-MF) in 14.5% (16/110). Thrombocytopenia was common: median baseline platelet count was 63 ×10 9 /L, with 38.2% (42/110) 100 × 10 9 /L) in 66.7% vs. 28.7% in SF3B1 -WT patients, P = 0.004). Fig. 1: The mutation and cytokine profiles in the PAC203 cohort. A Waterfall plot of mutation distribution in the PAC203 cohort. B Forest plot illustrating the results of logistic regression analyses of mutation statuses and baseline hemoglobin count associated with the likelihood of grade 3/4 anemia; TET2 -mutated patients were more likely to experience grade 3/4 anemia independent of baseline hemoglobin level; odds ratio (OR) 4.5, 95% CI 1.4–13.9, P = 0.009 (upper panel). Forest plot illustrating the results of logistic regression analyses of mutation statuses and baseline platelet count associated with the likelihood of grade 3/4 thrombocytopenia; KRAS/NRAS -mutated patients were more likely to experience grade 3/4 anemia after adjustment for baseline platelet level; OR 3.65, 95% CI 1.2–11.3, P = 0.026. (lower panel). Univariate logistic regression was performed for each variable. Significant P values (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- NIHR Biomedical Research Centre and MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. jennifer.osullivan@rdm.ox.ac.uk.
- Department of Clinical Haematology, Guy's and St Thomas NHS Foundation Trust, London, UK. jennifer.osullivan@rdm.ox.ac.uk.
- Astex Pharmaceuticals, Inc., Pleasanton, CA, USA.
- Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
- CTI BioPharma Corp., Seattle, WA, USA.
- Department of Clinical Haematology, Guy's and St Thomas NHS Foundation Trust, London, UK.
Förderung
- Medical Research Council
- Cancer Research UK
- RCUK | Medical Research Council
Zitieren
APA
O'Sullivan, J. M., Taylor, J., Gerds, A., Buckley, S., Harrison, C. N., Oh, S., List, A. F., Howard, K., Dreau, H., Hamblin, A., & Mead, A. J. (2023). RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort. Leukemia. https://doi.org/10.1038/s41375-023-02027-3
Vancouver
O'Sullivan JM, Taylor J, Gerds A, Buckley S, Harrison CN, Oh S, et al. RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort. Leukemia. 2023. doi:10.1038/s41375-023-02027-3
BibTeX
@article{OSullivan2023,
author = {O'Sullivan, J M and Taylor, J and Gerds, A and Buckley, S and Harrison, C N and Oh, S and List, A F and Howard, K and Dreau, H and Hamblin, A and Mead, A J},
title = {RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort},
journal = {Leukemia},
year = {2023},
doi = {10.1038/s41375-023-02027-3}
}
EUVIMED